Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 05 Apr 2023
According to a new study led by UCL researchers, wearable technology like smart watches could be used to identify people who are more likely to experience heart failure and irregular heartbeats later in life.
Read Full NewsAvadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.
NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
Ophthalmology in 2025: Year in Review
Increases in Physician Attrition Rates Could Worsen Shortages
Hormonal Disorders in 2025: Year in Review
1.
Mouse study finds tirzepatide slowed obesity-associated breast cancer growth
2.
AI is useful in low-resource areas for triaging breast masses.
3.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
4.
When performed by skilled surgeons, robotic surgery for pancreatic tumors is safe and feasible.
5.
Financial hardship common in patients with cancer
1.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
2.
New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD)
3.
Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care
4.
Is AI The New Radiologist For Breast MRI?
5.
Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Updates on the First Line Management of ALK+ NSCLC
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge